Abstract:Background Emerging evidence has indicated possible efficacy benefit of platinum‐based chemotherapy as neoadjuvant treatment for invasive ductal carcinoma triple‐negative breast cancer (TNBC). However, it has not been endorsed by current guidelines due to highly controversial results. Materials and Methods Present study aims to investigate predictive and prognostic roles concerning single nucleotide polymorphisms (SNPs) in XRCC1 and BRCA1, BRCA2 genes for early stage TNBC patients that received platinum‐based neoadjuvant treatment. We prospectively enrolled women with stage IIB‐IIIB TNBC that had progressed on neoadjuvant taxane and anthracycline‐based chemotherapy at Xinjiang Medical University Affiliated Cancer Hospital. Tumor response and pathological complete response (pCR) rate were assessed. Invasive disease‐free survival (iDFS) and overall survival (OS) were analyzed. Patients' blood samples were subject to Sanger sequencing to genotype XRCC1 Arg194Trp and Arg399Gln, BRCA1 s1799949, and BRCA2 rs206115. Univariate and multivariate logistic regressions were employed to investigate associations between SNPs and clinical characteristics with treatment response and pCR. A total of 45 patients were enrolled. Results The cohort showcased ORR of 44.4%, pCR of 28.9%, median iDFS of 22 months, and a 3‐year OS of 73.3%. The A/G and G/G genotypes of BRCA1 rs1799949, and the T/T genotype of BRCA2 rs206115 were associated with higher responsive rate. Histologic grade of III and Ki67 expression > 65% were associated with low responsive rate. Moreover, the A/G genotype of BRCA1 rs1799949 and T/T genotype of BRCA2 rs206115 correlated to high pCR. The histologic III and T4 stage correlated to inferior iDFS. Carrier of BRCA1 rs1799949 G/G had the most favorable OS, carriers of A/A showed the poorest OS, and those with A/G genotype showed an intermediate OS. Conclusions Platinum‐based chemotherapy might serve as a therapeutic option for TNBC patients who were resistant to anthracycline‐ and taxane‐based neoadjuvant therapy. Our study identified several genetic and clinical features that might function as prognostic and predictive markers.

Genetic variations in the PI3K/AKT pathway predict platinum-based neoadjuvant chemotherapeutic sensitivity in squamous cervical cancer

Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer

Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.

PI3K/PTEN/AKT/mTOR Pathway Genetic Variation Predicts Toxicity and Distant Progression in Lung Cancer Patients Receiving Platinum-Based Chemotherapy.

Genetic Alterations of PIK3CA and Tumor Response in Patients with Locally Advanced Cervical Squamous Cell Carcinoma Treated with Cisplatin-Based Concurrent Chemoradiotherapy.

Genome-wide association study identifies four SNPs associated with response to platinum-based neoadjuvant chemotherapy for cervical cancer

Association Between Polymorphisms of Autophagy Pathway and Responses in Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy.

Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer

The Association of XRCC1 Gene Single Nucleotide Polymorphisms with Response to Neoadjuvant Chemotherapy in Locally Advanced Cervical Carcinoma.

Genetic variation in AKT1 and AKT2 is associated with variation in recurrence free survival following cisplatin treatment of esophageal cancer

Single Nucleotide Polymorphism in ERCC1 118C→T Predicts the Outcome of NSCLC Patients Receiving Platinum-Based Chemotherapy

Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy.

The Association of Genetic Variations in DNA Repair Pathways with Severe Toxicities in NSCLC Patients Undergoing Platinum-Based Chemotherapy.

Somatic alterations of TP53, ERBB2, PIK3CA and CCND1 were associated with chemosensitivity for breast cancers.

Gene polymorphism and prediction of toxicity to platinum-based chemotherapy in patients with gynecologic cancer

Association of Cdc25 Phosphatase Family Polymorphisms with the Efficacy/Toxicity of Platinum-Based Chemotherapy in Chinese Advanced Nsclc Patients

Genomic Correlates of Unfavorable Outcome in Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemoradiation

Genetic Polymorphisms and Treatment Response in Advanced Non-Small Cell Lung Cancer.

A pharmacogenetics study of platinum- based chemotherapy in lung cancer: <i>ABCG2</i> polymorphism and its genetic interaction with <i>SLC31A1</i> are associated with response and survival

Single Nucleotide Polymorphisms in XRCC1 and Clinical Response to Platin-based Chemotherapy in Advanced Non-small Cell Lung Cancer

Prognostic and Predictive Markers for Early Stage Triple‐Negative Breast Cancer Treated With Platinum‐Based Neoadjuvant Chemotherapy